-
Uncategorized7 days agoSTAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
Uncategorized7 days ago
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
-
Uncategorized7 days ago
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.
-
Uncategorized7 days agoA trend that isn’t fading, ultra-processed baby foods
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. In a search for silver linings...
-
Uncategorized7 days agoLeriglitazone gets positive EU opinion for rare neurodegenerative disease
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for Nezglyal (leriglitazone) as...
-
Uncategorized7 days ago
From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026. Read More
-
Uncategorized7 days agoSTAT+: Argenx to buy Forte Biosciences for $2.2B
Argenx said Monday it would buy Forte Biosciences to expand its immunology pipeline, continuing the sector’s acquisition run, as even midsize companies hunt for pick-up targets. ...
-
Uncategorized7 days ago
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
Investment and a maturing talent base have propelled Denmark ahead of its Nordic peers, drawing Swedish companies and exposing regional gaps in capital and scale.
-
Uncategorized7 days agoStockWatch: Axiom CEO Explains Plans for Hong Kong IPO
StockWatch: Axiom CEO Explains Plans for Hong Kong IPO
-
Uncategorized7 days ago
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be...
StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel
STAT+: Senate measure would block Trump plan to politicize federal grants, for now
